SI1056729T1 - N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl)guanidine derivatives for the treatment of ischemia - Google Patents
N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl)guanidine derivatives for the treatment of ischemiaInfo
- Publication number
- SI1056729T1 SI1056729T1 SI9930743T SI9930743T SI1056729T1 SI 1056729 T1 SI1056729 T1 SI 1056729T1 SI 9930743 T SI9930743 T SI 9930743T SI 9930743 T SI9930743 T SI 9930743T SI 1056729 T1 SI1056729 T1 SI 1056729T1
- Authority
- SI
- Slovenia
- Prior art keywords
- triaza
- ischemia
- membered
- carbonyl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7636298P | 1998-02-27 | 1998-02-27 | |
| EP99901083A EP1056729B1 (fr) | 1998-02-27 | 1999-02-05 | Derives de la n- (a cycle di ou triaza diinsature substitue) carbonyle] guanidine utilises pour le traitement de l'ischemie |
| PCT/IB1999/000206 WO1999043663A1 (fr) | 1998-02-27 | 1999-02-05 | Derives de la n-[(a cycle di ou triaza diinsature substitue) carbonyle] guanidine utilises pour le traitement de l'ischemie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1056729T1 true SI1056729T1 (en) | 2005-04-30 |
Family
ID=22131525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9930743T SI1056729T1 (en) | 1998-02-27 | 1999-02-05 | N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl)guanidine derivatives for the treatment of ischemia |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US6492401B1 (fr) |
| EP (2) | EP1454902A1 (fr) |
| JP (2) | JP2002504546A (fr) |
| KR (4) | KR100407903B1 (fr) |
| CN (1) | CN1289326A (fr) |
| AP (1) | AP9901478A0 (fr) |
| AR (1) | AR015526A1 (fr) |
| AT (1) | ATE286034T1 (fr) |
| AU (1) | AU739403B2 (fr) |
| BG (1) | BG104803A (fr) |
| BR (1) | BR9908332A (fr) |
| CA (1) | CA2321642A1 (fr) |
| CO (1) | CO4980897A1 (fr) |
| DE (1) | DE69922930T2 (fr) |
| DK (1) | DK1056729T3 (fr) |
| DZ (1) | DZ2729A1 (fr) |
| EA (1) | EA003603B1 (fr) |
| ES (1) | ES2237080T3 (fr) |
| GT (1) | GT199900022A (fr) |
| HR (2) | HRP20000550A2 (fr) |
| HU (1) | HUP0204418A3 (fr) |
| ID (1) | ID25505A (fr) |
| IL (1) | IL136588A0 (fr) |
| IS (1) | IS5548A (fr) |
| NO (1) | NO20004192D0 (fr) |
| NZ (1) | NZ504769A (fr) |
| OA (1) | OA11450A (fr) |
| PA (1) | PA8468401A1 (fr) |
| PE (1) | PE20000334A1 (fr) |
| PL (1) | PL342444A1 (fr) |
| PT (1) | PT1056729E (fr) |
| SI (1) | SI1056729T1 (fr) |
| SK (1) | SK12342000A3 (fr) |
| TN (1) | TNSN99028A1 (fr) |
| TR (1) | TR200002480T2 (fr) |
| TW (1) | TWI226329B (fr) |
| WO (1) | WO1999043663A1 (fr) |
| YU (1) | YU46200A (fr) |
| ZA (1) | ZA991578B (fr) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU739403B2 (en) * | 1998-02-27 | 2001-10-11 | Pfizer Products Inc. | N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia |
| FR2795726A1 (fr) * | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| UA72002C2 (en) * | 1999-10-29 | 2005-01-17 | Pfizer Prod Inc | Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage |
| US6441176B1 (en) * | 1999-10-29 | 2002-08-27 | Pfizer Inc. | Method for preparing sodium-hydrogen exchanger type 1 inhibitor |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| JP2004501083A (ja) | 2000-04-18 | 2004-01-15 | アゴーロン・ファーマシューティカルズ・インコーポレイテッド | プロテインキナーゼを阻害するためのピラゾール |
| US6852733B2 (en) | 2000-04-28 | 2005-02-08 | Pfizer Inc. | Sodium-hydrogen exchanger type 1 inhibitor |
| PL357765A1 (en) * | 2000-04-28 | 2004-07-26 | Pfizer Products Inc. | Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) |
| IL144507A0 (en) * | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| EP1337508A1 (fr) * | 2000-11-28 | 2003-08-27 | Pfizer Products Inc. | Preparation d'inhibiteurs de type 1 d'echangeur de sodium-hydrogene |
| US6423705B1 (en) | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
| IL147696A0 (en) * | 2001-01-25 | 2002-08-14 | Pfizer Prod Inc | Combination therapy |
| JP2004518686A (ja) * | 2001-01-31 | 2004-06-24 | ファイザー・プロダクツ・インク | ナトリウム−水素交換輸送体１型阻害剤のエタノラート |
| WO2002098429A1 (fr) * | 2001-06-07 | 2002-12-12 | Pfizer Products Inc. | Formes salines du zopolrestat, a savoir ethanolamine, diethanolamine ou triethanolamine |
| WO2003002062A2 (fr) * | 2001-06-29 | 2003-01-09 | Tularik Inc. | Derives de bis-aryl thiazole |
| JP2005511590A (ja) * | 2001-11-02 | 2005-04-28 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | アデノシンａ１／ａ２アゴニストおよびナトリウム水素交換体阻害剤を含む医薬組成物 |
| EP1456181A1 (fr) | 2001-12-19 | 2004-09-15 | Pfizer Products Inc. | Methodes de preparation d'inhibiteurs de type 1 d'echangeurs de sodium-hydrogene |
| EP1472242A1 (fr) * | 2002-01-30 | 2004-11-03 | Pfizer Products Inc. | Compositions pharmaceutiques de zoniporide mesylate et procedes d'amelioration de la solubilite du zoniporide |
| MXPA04008646A (es) * | 2002-05-02 | 2004-12-06 | Pfizer Prod Inc | Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1. |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| FR2840302B1 (fr) | 2002-06-03 | 2004-07-16 | Aventis Pharma Sa | Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| FR2842526B1 (fr) | 2002-07-16 | 2007-07-13 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments |
| FR2842524B1 (fr) * | 2002-07-16 | 2005-04-22 | Aventis Pharma Sa | Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-pyrrole, leur procede de preparation a titre de medicaments |
| FR2842525B1 (fr) * | 2002-07-16 | 2005-05-13 | Aventis Pharma Sa | Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant |
| AU2003297629A1 (en) * | 2002-12-04 | 2004-06-23 | Ore Pharmaceuticals Inc. | Modulators of melanocortin receptor |
| CN100436445C (zh) * | 2003-02-07 | 2008-11-26 | 第一制药株式会社 | 吡唑衍生物 |
| US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| PL1689757T3 (pl) | 2003-11-12 | 2015-05-29 | Sino Med Int Alliance Inc | Heterocykliczne związki kwasu boronowego |
| US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| TW200526641A (en) * | 2003-12-26 | 2005-08-16 | Daiichi Seiyaku Co | Amidopyrazole derivatives |
| WO2005079803A1 (fr) * | 2004-02-13 | 2005-09-01 | Pfizer Products, Inc. | Composes pour traitement des maladies cardio-vasculaires |
| EP1778220A1 (fr) | 2004-07-12 | 2007-05-02 | Phenomix Corporation | Composes cyano contraints |
| WO2006055435A1 (fr) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | Derives de 2-aminonaphtalene et inhibiteurs de la glycogene phosphorylase associes |
| US7214704B2 (en) | 2004-11-15 | 2007-05-08 | Bristol-Myers Squibb Company | 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006055462A1 (fr) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | Derives 2-amino-4- tetraline fonctionnalisee et inhibiteurs de la glycogene phosphorylase associes |
| PT1853296E (pt) * | 2005-01-10 | 2012-09-26 | Debiopharm Sa | Utilização de um undecapeptídeo cíclico para a preparação de um medicamento para administração em situações de miocardia isquêmica |
| EP1879881A2 (fr) | 2005-04-14 | 2008-01-23 | Bristol-Myers Squibb Company | Inhibiteurs de la 11-beta hydroxysteroide deshydrogenase de type i |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US8318941B2 (en) | 2006-07-06 | 2012-11-27 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US7727978B2 (en) | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| EP2142551B1 (fr) | 2007-04-17 | 2015-10-14 | Bristol-Myers Squibb Company | Composés HÉTÉROCYCLIQUEs CONDENSÉS comme INHIBITEURS DE la 11-béta-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE I |
| JP2010534722A (ja) | 2007-07-27 | 2010-11-11 | ブリストル−マイヤーズ スクイブ カンパニー | 新規グルコキナーゼ活性化薬およびその使用方法 |
| RU2531354C2 (ru) | 2008-04-28 | 2014-10-20 | Янссен Фармацевтика Нв | Бензоимидазолы как ингибиторы пролилгидроксилазы |
| US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
| ES2549005T3 (es) * | 2008-11-21 | 2015-10-22 | Raqualia Pharma Inc | Nuevo derivado de pirazol-3-carboxamida que tiene actividad antagonista del receptor 5-HT2B |
| WO2010094090A2 (fr) * | 2009-02-18 | 2010-08-26 | Katholleke Universiteit Leuven | Synucléinopathies |
| US8592396B2 (en) | 2010-04-14 | 2013-11-26 | Bristol-Myers Squibb Company | Glucokinase activators and methods of using same |
| CN102408385B (zh) * | 2011-06-20 | 2014-06-18 | 雅本化学股份有限公司 | 一种2-取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| CN102408386B (zh) * | 2011-07-27 | 2014-05-07 | 雅本化学股份有限公司 | 2,4-二取代-2h-1,2,3-三氮唑衍生物的制备方法 |
| US9226505B2 (en) | 2011-09-23 | 2016-01-05 | Bayer Intellectual Property Gmbh | 4-substituted 1-phenylpyrazole-3-carboxylic acid derivatives as agents against abiotic plant stress |
| BR112014009910B1 (pt) | 2011-10-25 | 2020-06-30 | Janssen Pharmaceutica N.V. | sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica |
| WO2013130411A1 (fr) | 2012-02-27 | 2013-09-06 | Essentialis, Inc. | Sels d'ouvreurs des canaux potassiques atp et leurs utilisations |
| AU2016301745B2 (en) * | 2015-08-06 | 2020-07-16 | Ube Industries, Ltd. | Substituted guanidine derivative |
| WO2017057695A1 (fr) * | 2015-09-30 | 2017-04-06 | 東レ株式会社 | Dérivé de diphénylpyrazol et son utilisation à des fins médicales |
| CN108430976B (zh) * | 2015-12-16 | 2022-07-05 | 日本曹达株式会社 | 芳基唑化合物和有害生物防除剂 |
| US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| CN108017584B (zh) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3腺苷受体的小分子拮抗剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2104931B1 (fr) * | 1970-09-08 | 1975-01-10 | Ferlux | |
| CA2121391A1 (fr) * | 1993-04-28 | 1994-10-29 | Atsuyuki Kojima | Derives d'indoloylguanidine |
| IL109570A0 (en) | 1993-05-17 | 1994-08-26 | Fujisawa Pharmaceutical Co | Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof |
| US5852046A (en) | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| EP0639573A1 (fr) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant |
| DE4412334A1 (de) * | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| CA2160600A1 (fr) | 1994-10-18 | 1996-04-19 | Masahumi Kitano | Derives de l'indoloylguanidine |
| NZ314105A (en) | 1996-02-02 | 1997-12-19 | Sumitomo Pharma | Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring |
| JPH09291076A (ja) * | 1996-04-24 | 1997-11-11 | Sumitomo Pharmaceut Co Ltd | 置換グアニジン誘導体およびその製法 |
| ZA9711102B (en) * | 1996-12-16 | 1998-08-13 | Yamanouchi Pharma Co Ltd | N-[(substituted 5-membered heteroaryl)carbonyl] guanidine derivative |
| AU739403B2 (en) * | 1998-02-27 | 2001-10-11 | Pfizer Products Inc. | N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia |
-
1999
- 1999-02-05 AU AU20706/99A patent/AU739403B2/en not_active Ceased
- 1999-02-05 KR KR10-2002-7017553A patent/KR100407903B1/ko not_active IP Right Cessation
- 1999-02-05 DK DK99901083T patent/DK1056729T3/da active
- 1999-02-05 PL PL99342444A patent/PL342444A1/xx not_active Application Discontinuation
- 1999-02-05 NZ NZ504769A patent/NZ504769A/en unknown
- 1999-02-05 AT AT99901083T patent/ATE286034T1/de not_active IP Right Cessation
- 1999-02-05 EP EP04008203A patent/EP1454902A1/fr not_active Withdrawn
- 1999-02-05 CN CN99802628A patent/CN1289326A/zh active Pending
- 1999-02-05 YU YU46200A patent/YU46200A/sh unknown
- 1999-02-05 CA CA002321642A patent/CA2321642A1/fr not_active Abandoned
- 1999-02-05 HU HU0204418A patent/HUP0204418A3/hu not_active Application Discontinuation
- 1999-02-05 JP JP2000533420A patent/JP2002504546A/ja active Pending
- 1999-02-05 IL IL13658899A patent/IL136588A0/xx unknown
- 1999-02-05 SK SK1234-2000A patent/SK12342000A3/sk unknown
- 1999-02-05 ID IDW20001633A patent/ID25505A/id unknown
- 1999-02-05 TR TR2000/02480T patent/TR200002480T2/xx unknown
- 1999-02-05 KR KR10-2003-7009644A patent/KR20030078886A/ko not_active Application Discontinuation
- 1999-02-05 US US09/367,731 patent/US6492401B1/en not_active Expired - Fee Related
- 1999-02-05 ES ES99901083T patent/ES2237080T3/es not_active Expired - Lifetime
- 1999-02-05 WO PCT/IB1999/000206 patent/WO1999043663A1/fr not_active Application Discontinuation
- 1999-02-05 PT PT99901083T patent/PT1056729E/pt unknown
- 1999-02-05 KR KR10-2003-7012300A patent/KR20030083004A/ko not_active Application Discontinuation
- 1999-02-05 SI SI9930743T patent/SI1056729T1/xx unknown
- 1999-02-05 KR KR10-2000-7009529A patent/KR100449600B1/ko not_active IP Right Cessation
- 1999-02-05 EP EP99901083A patent/EP1056729B1/fr not_active Expired - Lifetime
- 1999-02-05 DE DE69922930T patent/DE69922930T2/de not_active Expired - Fee Related
- 1999-02-05 BR BR9908332-9A patent/BR9908332A/pt not_active IP Right Cessation
- 1999-02-05 EA EA200000789A patent/EA003603B1/ru not_active IP Right Cessation
- 1999-02-22 TW TW088102574A patent/TWI226329B/zh active
- 1999-02-22 GT GT199900022A patent/GT199900022A/es unknown
- 1999-02-23 PE PE1999000156A patent/PE20000334A1/es not_active Application Discontinuation
- 1999-02-24 PA PA19998468401A patent/PA8468401A1/es unknown
- 1999-02-24 TN TNTNSN99028A patent/TNSN99028A1/fr unknown
- 1999-02-24 DZ DZ990032A patent/DZ2729A1/fr active
- 1999-02-25 AR ARP990100791A patent/AR015526A1/es unknown
- 1999-02-25 AP APAP/P/1999/001478A patent/AP9901478A0/en unknown
- 1999-02-26 ZA ZA9901578A patent/ZA991578B/xx unknown
- 1999-03-01 CO CO99012526A patent/CO4980897A1/es unknown
-
2000
- 2000-06-27 IS IS5548A patent/IS5548A/is unknown
- 2000-08-18 OA OA1200000223A patent/OA11450A/en unknown
- 2000-08-22 NO NO20004192A patent/NO20004192D0/no not_active Application Discontinuation
- 2000-08-24 HR HR20000550A patent/HRP20000550A2/hr not_active Application Discontinuation
- 2000-09-27 BG BG104803A patent/BG104803A/bg unknown
-
2001
- 2001-08-29 HR HR20010666A patent/HRP20010666A2/hr not_active Application Discontinuation
-
2002
- 2002-12-09 US US10/315,369 patent/US6974813B2/en not_active Expired - Fee Related
-
2004
- 2004-08-27 JP JP2004248129A patent/JP2005041879A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1056729T1 (en) | N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl)guanidine derivatives for the treatment of ischemia | |
| HUP0202807A3 (en) | Compounds for the treatment of ischemia | |
| HUP0202799A3 (en) | Herbicidal isoxazoline derivatives and composition containing the same | |
| PL350412A1 (en) | 2−amino−benzoxazinone derivatives for the treatment of obesity | |
| EP1198230A4 (fr) | Utilisation de creatine ou de composes de creatine pour la preservation de la peau | |
| HK1048636A1 (en) | N-(indolcarbonyl-)piperazin derivatives | |
| HU0100973D0 (en) | Use of heteroaryl substituted n-(indole-2-carbonyl)-amide derivatives for the treatment of infections | |
| ZA200400455B (en) | Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade. | |
| ZA200108905B (en) | Use of macrolide compounds for the treatment of dry eye. | |
| IL137365A0 (en) | Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| AU3078000A (en) | Heterocyclic compounds and antitumor agents containing the same as the active ingredient | |
| ZA9711102B (en) | N-[(substituted 5-membered heteroaryl)carbonyl] guanidine derivative | |
| DE69937692D1 (de) | Arzneimittel zur behandlung der hemicrania | |
| HUP0402072A3 (en) | Glycine derivatives containing 1,3-oxazole or -thiazole ring and drugs containing the same as active ingredient | |
| AU5844899A (en) | Composition, containing sublimed sulfur, for the treatment of lactose intolerance | |
| HUP0204144A3 (en) | N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses | |
| AU2002333843A1 (en) | Substituted n-(1,4,5,6-tetrahydrocyclopentapyrazol-3-yl) derivatives and the use of the same for the treatment of cancer | |
| SI1140919T1 (en) | 1,4-disubstituted cyclohexane derivatives for the treatment of depression | |
| PL336642A1 (en) | Novel derivatives of l-phenylglycine substituted at position 4 of their aromatic ring | |
| SI1054874T1 (en) | Substituted aminophenyl isoxazoline derivatives useful as antimicrobials | |
| SI1198453T1 (en) | N-(indolcarbonyl-)piperazin derivatives |